January 2026 updates to the Universal Influenza Vaccine Technology Landscape include the following: 

• Henry 2026 and Kaplonek 2025 analyzed humoral and cellular immune responses to Moderna’s mRNA-1010 vaccine candidate compared with FLUAD, a licensed adjuvanted inactivated influenza vaccine, in a randomized phase 1 trial (NCT05397223).
• Preliminary results from phase 3 efficacy studies of Moderna’s mRNA-1010 vaccine candidate were reported in a January 5, 2026 press release. Moderna announced that it filed for marketing authorization of mRNA-1010 with US, European, Canadian, and Australian regulatory agencies.  
• Lindert 2025 reported data from a randomized, phase 2a human challenge trial (ISRCTN13789612) on the safety, reactogenicity, vaccine efficacy, and viral load for Pfizer’s modRNA vaccine candidate compared with a licensed quadrivalent seasonal influenza vaccine.
• NIAID initiated a randomized phase 1 trial (NCT07340047) to evaluate the safety and immunogenicity of H1ssF (H1 HA stabilized stem ferritin nanoparticle) vaccine candidate, compared with Flucelvax, a licensed cell-based seasonal influenza vaccine.
• Anderson 2026 reported that DNA plasmid vaccines targeting HA from 18 HA subtypes, elicited cross-reactive antibodies, T cells, and heterologous protection against influenza virus infection in a murine model.

For more recent updates and additional information, see the Landscape.